Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS.

IF 3.4 4区 医学 Q2 RHEUMATOLOGY Clinical and experimental rheumatology Pub Date : 2025-03-13 DOI:10.55563/clinexprheumatol/1n8j8d
Fung Lam, Kar Li Chan, Chi Hung To, Chi Chiu Mok
{"title":"Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS.","authors":"Fung Lam, Kar Li Chan, Chi Hung To, Chi Chiu Mok","doi":"10.55563/clinexprheumatol/1n8j8d","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To study the relationship between disease activity and quality of life (QoL) in patients with systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).</p><p><strong>Methods: </strong>Consecutive patients fulfilling the ACR/SLICC criteria for SLE were recruited. Participants were asked to complete the validated Chinese version of the LupusPRO for QoL evaluation before disease activity assessment by SLE-DAS, SLE disease activity index (SLEDAI)-2K and Physician Global Assessment (PGA). Correlation between disease activity and LupusPRO scores, and the effect of SLE-DAS remission on QoL was studied. Patients with active SLE at baseline, defined as a PGA≥0.5, were re-evaluated after 6 months. The change in LupusPRO score was correlated with the change in SLE-DAS.</p><p><strong>Results: </strong>A total of 510 patients were studied (92.9% women; age 48.6 ±13.3 years). At baseline, SLE-DAS remission (score ≤2.08), mild (2.08-7.64) and moderate/high disease activity (>7.64) was present in 364(71.3%), 75(14.7%) and 71(13.9%) patients, respectively. SLE-DAS index-based remission (score ≤2.08 and prednisone ≤5 mg/day) was achieved in 337(66.1%) patients. SLE-DAS correlated significantly with SLEDAI-2K and PGA (rho 0.92 and 0.62, respectively; p<0.01 in both). Patients with SLE-DAS index-based remission reported a significantly higher LupusPRO health-related (HR) QoL score compared to those without (76.8 ±16.2 vs. 69.0 ±16.8; p<0.01). A total of 139 patients with PGA ≥0.5 at baseline were reassessed at month 6: 77(55.4%) patients had improvement in SLE-DAS and 61(43.9%) patients achieved SLE-DAS index-based remission. The change in SLE-DAS was significantly associated with an improvement in LupusPRO HRQoL score (rho -0.30; p<0.01).</p><p><strong>Conclusions: </strong>SLE-DAS remission was associated with better QoL in patients with SLE. Reduction in SLE-DAS over time correlates significantly with improvement in health-related QoL.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/1n8j8d","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To study the relationship between disease activity and quality of life (QoL) in patients with systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).

Methods: Consecutive patients fulfilling the ACR/SLICC criteria for SLE were recruited. Participants were asked to complete the validated Chinese version of the LupusPRO for QoL evaluation before disease activity assessment by SLE-DAS, SLE disease activity index (SLEDAI)-2K and Physician Global Assessment (PGA). Correlation between disease activity and LupusPRO scores, and the effect of SLE-DAS remission on QoL was studied. Patients with active SLE at baseline, defined as a PGA≥0.5, were re-evaluated after 6 months. The change in LupusPRO score was correlated with the change in SLE-DAS.

Results: A total of 510 patients were studied (92.9% women; age 48.6 ±13.3 years). At baseline, SLE-DAS remission (score ≤2.08), mild (2.08-7.64) and moderate/high disease activity (>7.64) was present in 364(71.3%), 75(14.7%) and 71(13.9%) patients, respectively. SLE-DAS index-based remission (score ≤2.08 and prednisone ≤5 mg/day) was achieved in 337(66.1%) patients. SLE-DAS correlated significantly with SLEDAI-2K and PGA (rho 0.92 and 0.62, respectively; p<0.01 in both). Patients with SLE-DAS index-based remission reported a significantly higher LupusPRO health-related (HR) QoL score compared to those without (76.8 ±16.2 vs. 69.0 ±16.8; p<0.01). A total of 139 patients with PGA ≥0.5 at baseline were reassessed at month 6: 77(55.4%) patients had improvement in SLE-DAS and 61(43.9%) patients achieved SLE-DAS index-based remission. The change in SLE-DAS was significantly associated with an improvement in LupusPRO HRQoL score (rho -0.30; p<0.01).

Conclusions: SLE-DAS remission was associated with better QoL in patients with SLE. Reduction in SLE-DAS over time correlates significantly with improvement in health-related QoL.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
18.90%
发文量
377
审稿时长
3-6 weeks
期刊介绍: Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.
期刊最新文献
Granzyme B producing regulatory B-cells in patients with giant cell arteritis. ChatGPT's response regarding ankylosing spondylitis-related questions. Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS. Effect of TNF-α blockers on reducing the risk of dementia in rheumatoid arthritis: a nationwide cohort study. Risk of cervical intraepithelial neoplasia during Janus kinase inhibitor treatment in patients with rheumatoid arthritis: a retrospective cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1